Aromatase inhibitors such as anastrozole, letrozole, and exemestane are highly effective endocrine therapies of postmenopausal, estrogen receptor (ER)-positive breast cancer, prolonging the disease-free survival (DFS) and overall survival (OS) [8–10]. Here, ESR1 is linked to breast cancer.